Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity

DOI10.2307/2532851MaRDI QIDQ4335592zbMATH OpenOpenAlexWikidataFDO

Authors Mark R. Conaway, Gina R. Petroni

Publication date 26 April 1999

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.2307/2532851

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cited in

(14)

• Efficacy and toxicity monitoring via Bayesian predictive probabilities in phase II clinical trials
• A hypothesis test of feasibility for external pilot trials assessing recruitment, follow-up, and adherence rates
• MULTINOMIAL PHASE II CANCER TRIALS INCORPORATING RESPONSE AND EARLY PROGRESSION
• Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes
• Bayesian predictive monitoring with bivariate binary outcomes in phase II clinical trials
• Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
• A Geometric Approach to Comparing Treatments for Rapidly Fatal Diseases
• Testing statistical hypotheses on stochastic ordering of discrete distributions
• A Bayesian Group Sequential Approach for Multiple Endpoints
• Ethical issues in oncology biostatistics
• Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials
• Graphical comparison of multivariate nonparametric location tests for restricted alternatives
• Directed walk designs for dose-response problems with competing failure modes
• Two-stage phase II trials with early stopping for effectiveness and safety as well as ineffectiveness or harm

This page was built for publication: Designs for Phase II Trials Allowing for a Trade-Off between Response and Toxicity

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4335592)